drugset / Trial / NCT07557121
Safety and Efficacy of AIV007 Periocular Injection in Patients With Neovascular Age-Related Macular Degeneration
RandomizedParallel-groupTriple-blindTreatment
Summary
The goal of this study is to evaluate whether AIV007 provides benefits to patients with neovascular age-related macular degeneration in improving vision and that it has an acceptable safety profile. Participants will receive either a periocular injection of AIV007 or intravitreal injection of Eylea (control arm) to the study eye and return to the clinic monthly for safety and efficacy observations and/or continued treatment. Participants may receive additional treatment(s) if they meet specified criteria.
Timeline
- Start
- 2026-07-01
- Primary completion
- 2027-06-30
- Completion
- 2027-08-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AIV007 | Unknown | 6 mg | Other |
| Subject | AIV007 | Unknown | 8 mg | Other |
| Comparator | Aflibercept | Protein / enzyme biologic | 2 mg | Intravitreal |